Back to Search

A Phase 2 Open-Label Study of Sacituzumab Govitecan (IMMU-132) in Subjects With Metastatic Solid Tumors

  • Protocol Number: 201905001
  • Principal Investigator: Waqar, Saiama
  • Cancer Types: Early Phase, Head & Neck, Lung

Learn more about this study at: clinicaltrials.gov

For more information on this trial, contact us here:

Phone
800-600-3606
Email
info@ccadmin.wustl.edu

Brief Summary

The primary objective of this study is to assess the objective response rate (ORR) of sacituzumab govitecan-hziy in adult participants with metastatic solid tumors.

Protocol Interventions

Sacituzumab Govitecan-hziy